Titlebook: Oncology in the Precision Medicine Era; Value-Based Medicine Ravi Salgia Book 2020 Springer Nature Switzerland AG 2020 oncology.cancer.prec

吹牛需要藝術(shù)

Directed

花費

Healthcare Perspective,treatments are improving the prognosis for many patients. Yet in the midst of this time, there is significant concern about the economic sustainability of delivering this care. Without a coherant value framework, that intergrates meaningful data about patients’ prognosis, goals of care, and therapeu

Climate

Lung Cancer,rs. Treatment with targeted agents for non-small cell lung cancer (NSCLC) and immunotherapy for both NSCLC and small-cell lung cancer (SCLC) are leading to improvement in clinical outcomes for patients. Genomic alterations in NSCLC define distinct subtypes with specific mechanisms leading to tumor g

秘方藥

Esophageal and Gastric Cancer,, MSI, and PD-L1 tumor biomarkers. The latter two only recently emerged in the past 2?years, and PD-L1 determination still remains imperfect with questions remaining on optimal cutoff levels and if timing of tumor sampling matters with the dynamic nature of activation of immune pathways. Ongoing cli

Spina-Bifida

Sarcomas,e more than 50 different histological subtypes. For most STS subtypes, cytotoxic chemotherapy still remains the principal treatment for advanced and metastatic disease. In the past several decades, our expanding understanding of cancer biology has revealed distinct molecular alterations responsible

學(xué)術(shù)討論會

Multiple Myeloma,iven by genetic changes and alterations in the bone marrow microenvironment. A large disparity in outcomes has been observed; accordingly, disease may be stratified into high and standard risk. Triplet regimens, including bortezomib-lenalidomide-dexamethasone, have become preferred regimens as induc

恫嚇

圣人

Colon Cancer,se from 1?year to nearly 3?years with some of these patients achieving long-term cure. This has been accomplished both by the development of novel agents such as anti-VEGF antibodies and anti-EGFR receptor antibodies and by better selecting the patients who should receive these therapies. This work

新奇